WAVE Life Sciences (NASDAQ:WVE) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of WAVE Life Sciences (NASDAQ:WVE) in a research note released on Wednesday morning,Zacks reports. The firm issued a strong-buy rating on the stock. HC Wainwright also issued estimates for WAVE Life Sciences’ Q4 2027 earnings at ($0.28) EPS.

Several other research firms have also recently commented on WVE. LADENBURG THALM/SH SH started coverage on WAVE Life Sciences in a research report on Thursday, October 1st. They set a “buy” rating and a $10.00 price objective on the stock. Citigroup reduced their price objective on WAVE Life Sciences from $24.00 to $19.00 and set a “buy” rating for the company in a report on Friday, July 31st. Zacks Research lowered WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Thursday, October 15th. Finally, William Blair assumed coverage on shares of WAVE Life Sciences in a report on Friday, October 16th. They set an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.89.

WAVE Life Sciences Stock Up 5.5%

Shares of NASDAQ WVE opened at $3.64 on Wednesday. WAVE Life Sciences has a twelve month low of $3.04 and a twelve month high of $21.73. The firm has a market cap of $717.92 million, a P/E ratio of -3.34 and a beta of -1.43. The company has a 50 day moving average of $4.13 and a 200 day moving average of $7.60.

WAVE Life Sciences (NASDAQ:WVE) last issued its earnings results on Tuesday, October 27th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.03. The business had revenue of $13.16 million for the quarter, compared to the consensus estimate of $4.51 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. As a group, equities analysts expect that WAVE Life Sciences will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling at WAVE Life Sciences

In other news, Director Heidi Wagner sold 7,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the transaction, the director directly owned 44,930 shares of the company’s stock, valued at $270,029.30. This represents a 13.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Adrian Rawcliffe sold 12,700 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total value of $67,183.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 23,564 shares of company stock worth $132,476 over the last three months. Insiders own 24.34% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of WVE. Readystate Asset Management LP bought a new stake in WAVE Life Sciences during the second quarter valued at approximately $27,465,000. Squarepoint Ops LLC raised its position in WAVE Life Sciences by 68.0% in the second quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock worth $14,766,000 after acquiring an additional 1,029,052 shares during the period. Pictet Asset Management Holding SA raised its position in WAVE Life Sciences by 42.6% in the first quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company’s stock worth $8,202,000 after acquiring an additional 343,226 shares during the period. Renaissance Technologies LLC boosted its stake in shares of WAVE Life Sciences by 152.6% during the 1st quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock worth $4,330,000 after acquiring an additional 360,800 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of WAVE Life Sciences by 12.4% during the 1st quarter. Bank of New York Mellon Corp now owns 361,204 shares of the company’s stock worth $2,619,000 after acquiring an additional 39,759 shares during the last quarter. Institutional investors own 89.73% of the company’s stock.

Key Stories Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported a third-quarter loss of $0.30 per share, narrower than the $0.33–$0.34 analyst consensus. Revenue of $13.16 million also substantially exceeded estimates of approximately $4.51 million, helping ease concerns about the company’s near-term financial performance. Wave Life Sciences Stock Rallies as Q3 Results Ease Loss Fears
• Positive Sentiment: The company said planning is underway for a registrational trial of WVE-006, its RNA-editing candidate for alpha-1 antitrypsin deficiency (AATD). An interim biomarker analysis could potentially support an accelerated-approval pathway, providing a meaningful future catalyst if the program continues to generate positive data. WAVE Life Sciences Reports Third Quarter Results and Business Update
• Positive Sentiment: Management’s earnings call and business update provided investors with additional detail on the development pipeline and upcoming clinical milestones, supporting optimism around WVE-006 and the company’s broader RNA-editing platform. WAVE Life Sciences Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Oppenheimer reduced its price target to $29 from $32 but maintained an Outperform rating. The lower target is a modest valuation reset, while the unchanged rating indicates the analyst remains constructive on WVE’s long-term prospects. Oppenheimer Adjusts WAVE Life Sciences Price Target
• Negative Sentiment: Despite the earnings beat, WAVE remains unprofitable, reporting a quarterly loss and maintaining substantial cash-burn risk as it funds clinical development. Analysts continue to forecast a full-year loss, leaving the stock highly dependent on future trial progress and financing conditions. WAVE Life Sciences Reports Q3 Loss and Tops Revenue Estimates

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.